Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab tocilizumab. treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
Clinical course of patients with chronic limb-threatening ischemia developing COVID-19Article Published on 2022-12-012022-11-16 Journal: Journal of cardiology [Category] 변종, [키워드] 30-Day mortality 95 % CI acute respiratory syndrome added Analysis association calculated Cardiovascular events caused chronic Chronic limb-threatening ischemia claudication clinical Clinical course confidence interval control group coronavirus Course COVID-19 COVID-19 pandemic COVID-19 patient Cox regression analysis demonstrated diagnosis of COVID-19 disease evaluate the effect hazard ratio Healthcare systems high risk increased risk initial IPW Ischemia Japan Mortality mortality risk omicron omicron variant. pandemic Patient patients patients with COVID-19 primary outcome measure Probability proportion reached Regression model reported significantly higher treated Treatment variant was used Weighting [DOI] 10.1016/j.jjcc.2022.07.010 PMC 바로가기
Protection against Omicron from Vaccination and Previous Infection in a Prison SystemArticle Published on 2022-11-102022-11-16 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Analysis B.1.1.529 B.1.617.2 booster collected Combination coronavirus Cox model dose doses effective Effectiveness estimate evaluate evaluated hazard ratio high-risk population Infection mRNA mRNA vaccination mRNA vaccine offered omicron Omicron variant prison protection ranged retrospective cohort risk of infection SARS-CoV-2 significantly more stratified System vaccination vaccine dose vaccine doses variant were used [DOI] 10.1056/NEJMoa2207082 PMC 바로가기
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of OmicronArticle Published on 2022-11-052022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI Admission caused Cohort cohort analysis COVID-19 COVID-19 hospitalization COVID-19 vaccines dose doses Effectiveness elderly Elderly cohort evaluated Follow-up hazard ratio Heterologous homologous Hospitalization ICU ICU treatment Immunity individuals intensive care omicron outcome protection reduced remained restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 Omicron variant severe COVID-19 vaccination Vaccine waned Waning vaccine effectiveness. [DOI] 10.1186/s12879-022-07814-4 PMC 바로가기
Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort studyArticle Published on 2022-11-032022-11-16 Journal: Scientific Reports [Category] SARS, 변종, [키워드] Ad26.COV2.S vaccine Alpha Apulia calculate ChAdOx1-S Cohort combined use conducted COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccination programme Cox regression model death deaths Delta variants dominant Effect Effectiveness Effects Electronic health record eligible estimate hazard ratio Hospital admission hospitalisation infections Italy mRNA-1273 of BNT162b2 Older outcome positive Protective reduced retrospective cohort study SARS-CoV-2 SARS-CoV-2 infections study period subject vaccination Vaccine variant variants waned were used yielding [DOI] 10.1038/s41598-022-23235-4 PMC 바로가기
Thromboprophylaxis with standard- vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulationResearch article Published on 2022-11-012022-10-05 Journal: Journal of clinical epidemiology [Category] 임상, [키워드] 28-day mortality 95% confidence interval Anticoagulants anticoagulation baseline bleeding Coagulopathy COVID-19 COVID-19 diagnosis COVID-19 drug treatment dose eligible Epidemiological methods estimate hazard ratio hospitalized COVID-19 hospitalized COVID-19 patient hospitalized COVID-19 patients intensity intermediate dose laboratory abnormality LMWH Low–molecular weight heparin Major Mortality objective Observational data Patient Result risk setting Spain Standard dose survival target Target trial emulation Thromboprophylaxis thrombosis thrombotic risk Trial [DOI] 10.1016/j.jclinepi.2022.08.006 [Article Type] Research article
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) StudyArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addition adopted Adverse adverse event AEs amplification antibodies CCP Clinical outcome competing Concentration conducted convalescent convalescent plasma coronavirus COVID-19 death defined donors dose response Effectiveness eligible evaluate evaluated event Fisher Gray hazard ratio heterogeneity high-risk population hospital hospital discharge immunology Inconclusive Infection Lower Mortality NAb Neutralizing antibodies neutralizing antibodies. neutralizing antibody observational study occurred participant Patient positive primary clinical outcome randomized control trial receiving Registered Research Respiratory Support Result risk SAEs SARS-CoV-2 SARS-CoV-2 nucleic acid screened Secondary outcomes severe COVID-19 Standard of care Support Symptom therapeutic therapy time titer Treatment [DOI] 10.1128/mbio.01751-22 PMC 바로가기
Modifications to student quarantine policies in K-12 schools implementing multiple COVID-19 prevention strategies restores in-person education without increasing SARS-CoV-2 transmission risk, January-March 2021Article Published on 2022-10-202022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료기술, [키워드] adjusted Asymptomatic close contact Community conducted COVID-19 COVID-19 case Cox regression model determine event hazard ratio incidence incidence of COVID-19 increase in K-12 no difference occurred offered participant prospective cohort study public schools quarantine reduce risk RT-PCR testing SARS-COV-2 infection SARS-CoV-2 transmission School tested Transmission [DOI] 10.1371/journal.pone.0266292 PMC 바로가기
Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19Article Published on 2022-10-172022-11-16 Journal: Frontiers in Cellular and Infection Microbiology [Category] meta-analysis, [키워드] 28-day mortality Analysis analyzed Anti-inflammatory anti-inflammatory drug benefit Clinical outcome clinical outcomes clinical status coronavirus disease COVID-19 COVID-19 pandemic decrease discharge Evidence hazard ratio hospital discharge Hospitalized hospitalized patient In-hospital medication Meta-analysis Mortality non-steroidal anti-inflammatory drug Nonsteroidal anti-inflammatory drugs NSAID NSAIDS outcome Patient patients with COVID-19 performed post-hoc question raised receive risk Safe severe COVID-19 severity Severity. significant increase survival Treatment Trial two group with COVID-19 [DOI] 10.3389/fcimb.2022.935280 PMC 바로가기
Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021Article Published on 2022-10-032022-11-16 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome adjusted Against coronavirus coronavirus 2 coronavirus disease Coverage COVID-19 COVID-19 vaccine Cox proportional hazard Critical Delta dose effective Effectiveness evaluated hazard ratio home Infection maintaining Moderna morbidity and mortality Nursing nursing home residents Pfizer-BioNTech preventing infection provided Rate resident respiratory retrospective cohort SARS-CoV-2 SARS-COV-2 infection second dose vaccination Vaccine vaccine effectiveness. was used [DOI] 10.1093/cid/ciac562 PMC 바로가기